Arkolith/Insider Trading/TNXP/Form 4/A

Lederman Seth

Chief Executive Officer, DirectorTonix Pharmaceuticals Holding Corp. (TNXP) · full profile →Form 4/A · filed Mar 6, 2024
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
3
0 non-derivative · 3 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 27, 2024Grant(A)235K—$0235K
Feb 27, 2024Grant(A)1.9M—$01.9M
Feb 27, 2024Grant(A)1.3M—$01.3M

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4/A filing (accession 0001999371-24-003168) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4/A XML